1. DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies. (25th January 2019) Authors: Chiorean, M; Su, C; Matsuoka, K; Orlando, A; Thorpe, A J; Nduaka, C I; Chapman, D S; Woodworth, D A; Lawendy, N; Friedman, G S; Cohen, R D Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S049 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P487 Tofacitinib for the treatment of ulcerative colitis: Analysis of infection rates from the OCTAVE clinical programme. (16th January 2018) Authors: Winthrop, K L; Loftus Jr, E V; Baumgart, D C; Reinisch, W; Thorpe, A J; Nduaka, C I; Lawendy, N; Chan, G; Pedersen, R D; Friedman, G S; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S351 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P619 Maintenance of efficacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission. (25th January 2019) Authors: Rubin, D T; Travis, S; Abraham, B P; Su, C; Lawendy, N; Fan, H; Woodworth, D A; Thorpe, A J; Nduaka, C I; Quirk, D; Reinisch, W Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S425 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗